Coegin Pharma AB ("Coegin" or the "Company") today provides an operational and strategic update regarding its commercialization activities and business planning.

Operational update - Follicopeptide®
The start-up of commercial production of Follicopeptide has been completed successfully. Delivered batch sizes have been adapted to balance market demand with delivery reliability, ensuring a stable and predictable supply chain. Quality controls are carried out on every batch to ensure consistently high product quality.

Planned deliveries of the Follicopeptide gel serum have been carried out fully according to plan to the Company's existing distribution partners, Gents and Hårklinikken. Production for upcoming deliveries is proceeding as scheduled and is in line with demand forecasts.

Follicopeptide is delivered in the syringe-like bottle selected by Coegin. Existing distribution partners have chosen to apply product labels themselves. Coegin also offers labeling as part of its delivery, and will, going forward, also offer laser printing of product text directly on the bottles.

The planned scale-up of production capacity is progressing according to plan and will take place gradually starting in January 2026, with further capacity increases during the following months to support market demand. 

Follicopeptide® product portfolio and pipeline development
Development of a complementary product has been completed successfully and is on track to be offered to distribution partners in the near term. Production of this complementary product is secured both internally and, if required, through external manufacturing partners. More detailed information regarding this product will be communicated separately.

Development of additional Follicopeptide-based formulations and products continues according to plan. The Company expects to communicate further updates on these initiatives during the coming months. 

Business development
Coegin is working actively to secure additional distributors in key markets during 2026, supporting continued international expansion.

Skin pigmentation - NPP-4
Development work on the pigmentation peptide NPP-4 will enter a new, intensive development phase during the coming months, based on a defined development plan targeting a planned market launch towards the end of 2026. Professor Desmond Tobin, the inventor behind NPP-4, supports the Company in this development work.

Financial Plan
As mentioned in the Q3 -25 report, The Company is preparing a financial plan for 2026 with the ambition of achieving a more balanced cash flow during the second half of 2026, while at the same time working to minimize dilution for existing shareholders and maximize shareholder value.

CEO comment
"2025 has been a year of execution, where we have established structured commercial operations according to plan. With production scaling ahead, a growing product portfolio and a clear development roadmap, we enter 2026 with confidence and focus on long-term value creation," says Jens Eriksson, CEO of Coegin Pharma AB.

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com

Attached files